Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168.6 USD | +1.89% | +7.84% | +8.78% |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
Jun. 06 | AbbVie's ovarian cancer therapy succeeds in mid-stage trial | RE |
ETFs positioned on AbbVie Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 169 M€ | +0.25% | - | |
0.34% | 45 M€ | 0.00% | - | |
0.33% | 562 M€ | -1.02% | ||
0.33% | 35 M€ | +10.04% | - | |
0.32% | 112 M€ | +4.86% | - | |
0.31% | 23 M€ | +8.61% | - | |
0.30% | 1 M€ | -.--% | - | |
0.28% | 306 M€ | +6.45% | - | |
0.28% | 39 M€ | +6.61% | - | |
0.24% | 12 M€ | +18.05% | - | |
0.23% | 17 M€ | +4.86% | - | |
0.21% | 7 M€ | +5.33% | - | |
0.21% | 32 M€ | +0.47% | - | |
0.21% | 17 M€ | +5.32% | - | |
0.20% | 105 M€ | +4.21% | - | |
0.20% | 3 M€ | +7.10% | - | |
0.19% | 17 M€ | +3.59% | - | |
0.17% | 32 M€ | +1.11% | - | |
0.16% | 6 M€ | +3.89% | ||
0.15% | 48 M€ | -0.11% | - | |
0.13% | 15 M€ | -1.62% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 292B | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B | |
+1.39% | 123B |
- Stock Market
- Equities
- ABBV Stock
- Funds and ETFs AbbVie Inc.